Latest & greatest articles for diclofenac

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on diclofenac or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on diclofenac and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for diclofenac

21. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial

The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial Brereton N, Winn B, Akehurst (...) R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of celecoxib plus a proton pump inhibitor (PPI), compared with diclofenac plus a PPI, for patients with osteoarthritis. The authors

NHS Economic Evaluation Database.2013

22. Diclofenac: public consultation on availability as a pharmacy medicine

Diclofenac: public consultation on availability as a pharmacy medicine Diclofenac: public consultation on availability as a pharmacy medicine Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Diclofenac: public consultation on availability as a pharmacy medicine From: Published: 7 August 2013 Therapeutic area: Public consultation launched on the continued availability of oral diclofenac as a pharmacy (P) medicine and on risk-minimisation measures advised (...) by the Commission on Human Medicines. Article date: August 2013 We have launched a public consultation on the continued availability of oral diclofenac as a pharmacy (P) medicine and in particular on risk-minimisation measures advised by the Commission on Human Medicines. Any comments can be emailed to ; alternatively they may be addressed to: Colette McCreedy, Self Medication Specialist and Unit Manager, MHRA, 3rd Floor, 151 Buckingham Palace Road, London SW1W 9SZ. Comments must arrive no later than 28 October

MHRA Drug Safety Update2013

23. Diclofenac: new contraindications and warnings

Diclofenac: new contraindications and warnings Diclofenac: new contraindications and warnings Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Diclofenac: new contraindications and warnings From: Published: 24 June 2013 Therapeutic area: , , and New recommenedations after a Europe-wide review of cardiovascular safety. Article date: June 2013 An increased risk of heart attack and stroke with some non-selective non-steroidal anti-inflammatory drugs (NSAIDs)—such as (...) diclofenac—is well recognised, particularly with long-term use of high doses and in patients who are already at high risk. Warnings for healthcare professionals and patients have been included in the product information and in the British National Formulary for some years. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee has recently recommended updates to the treatment advice for diclofenac in light of the findings of a Europe-wide review of the cardiovascular safety of NSAIDs

MHRA Drug Safety Update2013

24. Topical Administration of Diclofenac is as Effective as Systemic Administration in Alleviating Ailments of Temporomandibular Joint Disorder

Topical Administration of Diclofenac is as Effective as Systemic Administration in Alleviating Ailments of Temporomandibular Joint Disorder UTCAT2225, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Topical Administration of Diclofenac is as Effective as Systemic Administration in Alleviating Ailments of Temporomandibular Joint Disorder Clinical Question In a patient suffering from Temporomandibular Joint Disorder (...) , is topical administration of treatment as effective when compared to systemic administration of treatment in alleviating ailments? Clinical Bottom Line Topical administration of diclofenac is as effective as systemic administration in alleviating ailments of temporomandibular joint disorder. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Di Rienzo/2004 36 adult patients diagnosed with dysfunction of the TMJ

UTHSCSA Dental School CAT Library2012

25. Efficacy of Oral Enzyme Combination vs. Diclofenac in the Management of Large Joint Osteoarthritis: A Systematic Review

Efficacy of Oral Enzyme Combination vs. Diclofenac in the Management of Large Joint Osteoarthritis: A Systematic Review "Efficacy of Oral Enzyme Combination vs. Diclofenac in the Management o" by Scott T. Hall < > > > > > Title Author Date of Award Summer 8-9-2012 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Annjanette Sommers PA-C, MS Rights . Abstract Background: Osteoarthritis is the most common (...) and trypsin. The purpose of this review is to evaluate the efficacy of oral enzyme combinations to the potent NSAID diclofenac in the management of osteoarthritis. Method: An extensive literature search was done using CINHAL, Medline, Evidence-Based Medicine Reviews Multifile, and Web of Science. The search included the terms Bromelain, Arthritis and Non-Steroidal Anti-inflammatory agents. Results: Five randomized control trials met the inclusion criteria. Each study was very similar with respect to study

Pacific University EBM Capstone Project2012

26. Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions

Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions Taylor RS, Fotopoulos G, Maibach H CRD summary The review concluded that topical diclofenac appeared to be generally well (...) tolerated for cutaneous use in acute and chronic musculoskeletal conditions. The differences across the studies, small sample sizes and uncertain methodological quality of included trials limits the reliability of the pooled results so the authors’ conclusions should be interpreted with a degree of caution. Authors' objectives To evaluate the risk of adverse events with topical diclofenac for the treatment of acute and chronic musculoskeletal conditions. Searching MEDLINE was searched to March 2010

DARE.2011

27. Diclofenac (Mobigel Spray) - For the local symptomatic relief of mild to moderate pain and inflammation following acute blunt trauma of small and medium-sized joints and periarticular structures

Diclofenac (Mobigel Spray) - For the local symptomatic relief of mild to moderate pain and inflammation following acute blunt trauma of small and medium-sized joints and periarticular structures Published 13 December 2010 Statement of Advice diclofenac 4% spray gel (Mobigel Spray ®) (No: 667/10) Goldshield Group Plc 05 November 2010 ADVICE: in the absence of a submission from the holder of the marketing authorisation diclofenac 4% spray gel (Mobigel Spray ®): is not recommended for use within

Scottish Medicines Consortium2011

28. Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries

Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries Kuehl KS CRD summary The review concluded that diclofenac epolamine (...) topical patch 1.3% significantly reduced pain in patients with soft tissue injuries and was well tolerated. Given the potential for bias in the review and the limitations of the small evidence base (such as uncertain quality and heterogeneity), the author's conclusions should be interpreted with caution. Authors' objectives To assess the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in the treatment of patients with acute pain due to soft tissue injuries. Searching MEDLINE

DARE.2010

29. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. 20638563 2010 07 19 2010 07 29 2015 11 19 1474-547X 376 9736 2010 Jul 17 Lancet (London, England) Lancet Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. 173-9 10.1016/S0140-6736(10)60673-3 Cyclo-oxygenase (COX)-2-selective non-steroidal anti-inflammatory drugs (NSAIDs) and non-selective (...) NSAIDs plus a proton-pump inhibitor (PPI) have similar upper gastrointestinal outcomes, but risk of clinical outcomes across the entire gastrointestinal tract might be lower with selective drugs than with non-selective drugs. We aimed to compare risk of gastrointestinal events associated with celecoxib versus diclofenac slow release plus omeprazole. We undertook a 6-month, double-blind, randomised trial in patients with osteoarthritis or rheumatoid arthritis at increased gastrointestinal risk at 196

Lancet2010

30. Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness

Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness Tsakonas E, Argaez C Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Tsakonas E, Argaez C. Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions The studies reviewed for this report suggest that in general, topical diclofenac (in gel and patch formulations), is safe and effective

Health Technology Assessment (HTA) Database.2009

31. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac

Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac 18823986 2008 11 10 2008 11 25 2016 11 24 1528-0012 135 5 2008 Nov Gastroenterology Gastroenterology Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. 1517-25 10.1053/j.gastro.2008.07.067 (...) Nonsteroidal anti-inflammatory drugs (NSAIDs) cause lower gastrointestinal (GI) clinical events such as bleeding. Cyclo-oxygenase (COX)-2 selective inhibitors decrease upper GI events, but no prospective trial has prespecified assessment of lower GI clinical events. Patients >or=50 years old with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 or 90 mg qd) or diclofenac (150 mg qd). Lower GI clinical events, confirmed by a blinded adjudication committee, included perforation or obstruction

EvidenceUpdates2008

32. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II)

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II) 17965424 2008 02 22 2008 03 04 2016 11 24 1468-2060 67 3 2008 Mar Annals of the rheumatic diseases Ann. Rheum. Dis. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). 315 (...) -22 A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA). A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054). Use of gastroprotective agents and low-dose aspirin was allowed. The prespecified primary end point consisted of the cumulative rate of patient

EvidenceUpdates2008

34. Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain

Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain Article Text Therapeutics Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish

Evidence-Based Medicine (Requires free registration)2008

35. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial.

Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. 17993364 2007 11 12 2007 11 20 2015 06 16 1474-547X 370 9599 2007 Nov 10 Lancet (London, England) Lancet Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. 1638-43 We aimed to investigate whether the addition (...) of non-steroidal anti-inflammatory drugs or spinal manipulative therapy, or both, would result in faster recovery for patients with acute low back pain receiving recommended first-line care. 240 patients with acute low back pain who had seen their general practitioner and had been given advice and paracetamol were randomly allocated to one of four groups in our community-based study: diclofenac 50 mg twice daily and placebo manipulative therapy (n=60); spinal manipulative therapy and placebo drug (n

Lancet2007

36. Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee

Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee Article Text Therapeutics Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis

Evidence-Based Medicine (Requires free registration)2006

38. The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis

The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis Pope J E, Prashker (...) M, Anderson J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of combination therapy with diclofenac (50 mg) and misoprostol (Arthrotec; 200 microg twice daily) for the treatment of patients with symptomatic

NHS Economic Evaluation Database.2004

39. Single dose oral diclofenac for postoperative pain.

Single dose oral diclofenac for postoperative pain. BACKGROUND: Diclofenac is a benzene-acetic acid derivative that acts, like other NSAIDs, by inhibiting cyclo-oxygenase isoforms that mediate the body's production of the prostaglandins implicated in pain and inflammation. Diclofenac is widely available as a sodium or potassium salt. Diclofenac potassium tablets are known as 'immediate-release' diclofenac as absorption takes place in the gastrointestinal tract whereas 'delayed-release' (enteric (...) -coated) diclofenac tablets resist dissolution until reaching the duodenum. An existing review showed that diclofenac was an effective treatment for acute postoperative pain but did not address the distinction between potassium and sodium salts due to lack of data. The aim of this update is to gather and add appropriate information published subsequently and, data permitting, examine any potential differences between the two different diclofenac formulations. OBJECTIVES: To assess single dose oral

Cochrane2004

40. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial

Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial von Scheele B, Pena B, Wong J, Niculescu L Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Valdecoxib (20 mg once daily), an oral cyclooxygenase (COX)-2-specific inhibitor, was compared with diclofenac (75 mg twice daily), a non-specific non-steroidal anti-inflammatory drug (NSAID), for the

NHS Economic Evaluation Database.2003